Review
Oncology
Tingting Yang, Lihua Kang, Dan Li, Yanqiu Song
Summary: Immunotherapy is a promising treatment for advanced breast cancer, particularly for triple-negative and HER2+ breast cancers. Monoclonal antibodies like trastuzumab, pertuzumab, and T-DM1 have proven effective in treating HER2+ breast cancers and have improved patient survival. Immune checkpoint inhibitors targeting PD-1/PD-L1 have also shown benefits in clinical trials. Adoptive T-cell immunotherapies and tumor vaccines are new approaches that require further study.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begona Bermejo, Juan Miguel Cejalvo
Summary: The aim of this review is to study the role of immune response in HER2+ breast cancer, summarize the interaction between the tumor microenvironment and anti-HER2 targeted therapies, and explore the implementation of immune modulators in clinical practice. Understanding the biological aspects of immune response is crucial for developing new treatment strategies.
Review
Medicine, General & Internal
Qiancheng Hu, Wenli Kang, Qingfeng Wang, Ting Luo
Summary: It is currently unclear which cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, combined with endocrine therapy, is the preferred treatment approach in patients with hormone receptor (HR)-positive, human epidermal receptor-2 (HER2) negative metastatic breast cancer. This study aims to evaluate the comparative efficacy, safety, and cost-effectiveness of different CDK4/6 inhibitors for metastatic breast cancer in first-line and second-line settings.
Review
Oncology
Leopoldo Sitia, Marta Sevieri, Lorena Signati, Arianna Bonizzi, Arianna Chesi, Francesco Mainini, Fabio Corsi, Serena Mazzucchelli
Summary: Breast cancer is a major cause of death in females worldwide, and nanotechnologies have shown significant potential in improving both therapeutic and diagnostic aspects, especially in HER-2-positive breast cancer. This review provides an update on the most promising nanoparticle-based approaches developed in the last decade for HER-2-positive breast cancer therapy and diagnosis.
Article
Chemistry, Analytical
Shayalini Wignarajah, Iva Chianella, Ibtisam E. Tothill
Summary: In this study, two biosensors were developed using gold sensor chips and amperometric detection to detect breast cancer. The sensors relied on sandwich enzyme-linked immunosorbent assays with monoclonal antibodies against HER-1 and HER-2 to capture the biomarkers. The results showed that the sensors had good detection capabilities within the clinical range for HER-1 and HER-2, and the use of gold nanoparticles further enhanced the sensitivity.
Review
Biochemistry & Molecular Biology
Marek Ziobro, Aleksandra Grela-Wojewoda
Summary: Patients with HR-positive, HER2-negative breast cancer constitute the majority of breast cancer population. CDK4/6 inhibitors have significantly improved the outcomes as first-line treatment for these patients. However, access to CDK4/6 inhibitors in Poland is limited to patients participating in the drug program, which may pose challenges for both patients and clinicians.
Review
Pharmacology & Pharmacy
Xueqiong Xun, Jun Ai, Fuhui Feng, Pan Hong, Saroj Rai, Ruikang Liu, Baowen Zhang, Yeming Zhou, Huiyong Hu
Summary: This meta-analysis found that the use of Bevacizumab in patients with triple-negative breast cancer and HER-2 negative metastatic breast cancer may increase the incidence of serious adverse events, indicating a need for caution in its usage.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Odelia Cooper, Vivien S. Bonert, Jeremy Rudnick, Barry D. Pressman, Janet Lo, Roberto Salvatori, Kevin C. J. Yuen, Maria Fleseriu, Shlomo Melmed
Summary: This study evaluated the effect of lapatinib, a tyrosine kinase inhibitor, on aggressive prolactinomas that are resistant to dopamine agonist therapy. While none of the participants achieved the primary endpoint, three showed stable disease and lapatinib was generally well tolerated with reversible side effects.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Medicine, Research & Experimental
Yuhao Ye, Zhiyu Huang, Maoqing Zhang, Jiayue Li, Yiqiong Zhang, Chenghua Lou
Summary: The activation of PI3K signaling pathway is linked to endocrine resistance and poor prognosis in cancers. Alpelisib, a selective PI3K inhibitor, has shown effectiveness in combination with endocrine therapy for HR+ PIK3CA-mutated advanced breast cancer. Recent studies have reported synergistic effects of alpelisib combined with targeted agents in various PIK3CA-mutated cancers. However, the synergistic potential of alpelisib in other cancers has not been well-reviewed. This review summarizes the preclinical and clinical studies of alpelisib in combination with targeted anti-cancer agents, excluding breast cancer, and provides insights and prospects for future combination studies.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li
Summary: This study aimed to investigate the correlation between HER-2 status and pathological complete response (pCR) in HER-2-positive breast cancer patients after dual anti-HER-2 neoadjuvant therapy with trastuzumab and pertuzumab. The study found that the HER-2/CEP17 ratio and HER-2/cell number ratio were crucial for predicting treatment efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Xu Han, Zhesheng He, Wenchao Niu, Chunyu Zhang, Zhongying Du, Xueyun Gao, Gengmei Xing
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with no effective targeted therapy available. Accurate quantification of HER-2 expression in breast cancer cells is important for diagnosis and treatment.
Article
Oncology
Manon Reda, Anais Fouquier, Isabelle Desmoulins, Didier Mayeur, Coureche Kaderbhai, Silvia Ilie, Audrey Hennequin, Bruno Coudert, Aurelie Bertaut, Sylvain Ladoire
Summary: This study retrospectively evaluated the clinical characteristics, treatment efficacy, and survival of 756 breast cancer patients, and found that taxane rechallenge had good efficacy and acceptable tolerance in patients with metastatic breast cancer, especially when these drugs have shown clinical activity earlier in the disease course.
Article
Pharmacology & Pharmacy
Min Ye, Wei Huang, Rui Liu, Yingli Kong, Yang Liu, Xiaole Chen, Jianhua Xu
Summary: The study demonstrated that the combination treatment of ganetespib and lapatinib has synergistic inhibitory effects on HER2-positive breast cancer cells, enhancing antitumor activity through multiple pathways.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Materials Science, Characterization & Testing
Ruiling Xu, Junhui Sui, Mingda Zhao, Yuedi Yang, Lei Tong, Yongmei Liu, Yong Sun, Yujiang Fan, Jie Liang, Xingdong Zhang
Summary: This study developed trastuzumab functionalized nanoparticles for the treatment of HER-2 positive breast cancer cells. The results showed significant cell uptake and cytotoxic effect in HER-2 positive cells, while no differences were observed in HER-2 negative cells.
Review
Oncology
Xiangting Jin, Min Yan, Fanfan Li
Summary: This case report highlights the potential therapeutic benefits of a combination of pyrotinib and capecitabine in HER-2 positive breast cancer patients with end-stage renal disease undergoing peritoneal dialysis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Cathelijne H. van der Wouden, Ellen Paasman, Martina Teichert, Matty R. Crone, Henk-Jan Guchelaar, Jesse J. Swen
JOURNAL OF CLINICAL MEDICINE
(2020)
Review
Medicine, General & Internal
Sylvia D. Klomp, Martijn L. Manson, Henk-Jan Guchelaar, Jesse J. Swen
JOURNAL OF CLINICAL MEDICINE
(2020)
Article
Pharmacology & Pharmacy
Essra Youssef, Charlotte L. Kirkdale, David J. Wright, Henk-Jan Guchelaar, Tracey Thornley
Summary: This study aims to quantitatively estimate the impact of a population-level pharmacogenetic screening programme on primary care prescribing in the UK. Results show that actionable drug-gene interactions are common in primary care, suggesting significant opportunities for optimizing prescribing practices.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Genetics & Heredity
Maaike van der Lee, Marjolein Kriek, Henk-Jan Guchelaar, Jesse J. Swen
Article
Dermatology
Ruth Van Daele, Yves Debaveye, Robin Vos, Pascal Van Bleyenbergh, Roger J. Bruggemann, Erwin Dreesen, Omar Elkayal, Henk-Jan Guchelaar, Pieter Vermeersch, Katrien Lagrou, Isabel Spriet
Summary: The CYP3A4/5 genotype plays a crucial role in determining the exposure to isavuconazole and may also impact the CYP450 induction interaction. Less potent CYP3A inducers compared to rifampin, such as rifabutin or phenobarbital, can be combined with isavuconazole in patients with loss of CYP3A5 activity (CYP3A5*3/*3). Therapeutic drug monitoring is recommended for this combination therapy.
Review
Pharmacology & Pharmacy
Maaike van der Lee, Henk-Jan Guchelaar, Jesse J. Swen
Summary: Genetic variants in the gene encoding CYP2D6 show substrate-specific effects in drug metabolism, with the CYP2D6*17 allele having higher debrisoquine clearance and the CYP2D6*10 allele having lower dextromethorphan clearance. However, more studies are needed due to sparse data on most substrates.
Review
Pharmacology & Pharmacy
Iris Lafeber, Elisabeth J. Ruijgrok, Henk-Jan Guchelaar, Kirsten J. M. Schimmel
Summary: 3D printing of pediatric-centered drug formulations offers a promising alternative to current treatment options and has shown superior dosing and release profiles compared to conventional methods. However, further research is needed for successful clinical implementation and expansion of regulatory guidance and product range.
Article
Chemistry, Medicinal
Henok D. Habtemariam, Henk-Jan Guchelaar
Summary: Pharmacogenomics studies the heritability of drug response, and individualizing drug therapy based on genetic profile can make drug therapy safer and more effective. Extracellular vesicles can be used to determine the expression of pharmacogenes in the liver.
Article
Chemistry, Medicinal
Lisanne E. N. Manson, Wilbert B. van den Hout, Henk-Jan Guchelaar
Summary: Implementing genotyping for HLA risk alleles in the Netherlands can potentially prevent drug hypersensitivity reactions and associated deaths in allopurinol and flucloxacillin initiators. However, genotyping before initiating antiepileptic drugs or flucloxacillin is not cost-effective.
Letter
Pharmacology & Pharmacy
Mirjam de With, Jonathan Knikman, Jan H. M. Schellens, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Ron H. J. Mathijssen, Jesse J. Swen, Didier Meulendijks
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Sylvia A. van Laar, Ellen Kapiteijn, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling
Summary: This study aimed to retrospectively review the benefits and risks of adjuvant melanoma treatments, finding that immune checkpoint inhibitors were better tolerated than D + T, but the adverse events of D + T were reversible. The study demonstrated that text-mining is a valuable method for collecting real-world data to evaluate melanoma treatments.
Article
Pharmacology & Pharmacy
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C. M. de Winter, Jesse J. J. Swen, Paul P. H. Le Brun, Erica C. M. Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A. R. Moes, Kirsten J. M. Schimmel
Summary: Personalized medicine lacks flexible drug formulations, especially for pediatric patients. This study investigates the feasibility of developing a 3D-printed tablet formulation at the point-of-care that complies with quality requirements for clinical practice, including bioequivalence.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Pharmacology & Pharmacy
Henk-Jan Guchelaar, Jesse Swen
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Sofia L. J. Peeters, Maarten J. Deenen, Anna M. J. Thijs, Emma C. Hulshof, Ron H. J. Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Article
Pharmacology & Pharmacy
Jonathan E. Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J. Deenen, Jan H. M. Schellens, Jos Beijnen, Annemieke Cats, Henk-Jan Guchelaar
Summary: DPYD-guided dosing has improved the safety of fluoropyrimidine-based chemotherapy. However, severe toxicity still occurs in patients without DPYD variant alleles. Therefore, researchers developed a predictive model based on patient and treatment factors to estimate the risk of severe toxicity. Internal validation showed good predictive ability of the model.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
